The association between MGMT promoter methylation and clinical outcome (using a 5 % cut-off value) comparing HRM, MSP, and PSQ was analyzed in tumor material of 65 IDH1 wt glioma patients (seven gliomas grade III and 58 grade IV). The gene discussed is MGMT; the disease is central nervous system cancer.